CHICAGO, IL -- February 26, 2007 -- PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today debuted at PITTCON® 2007, Booth 843, the new Spectrum™ Express software for its Spectrum™ One and Spectrum™ 100 series of FT-IR and FT-NIR instruments. Designed specifically for scientists in routine testing and academic teaching environments, the Spectrum Express offers efficient, “walk up and measure” ease-of-use and seamless integration with new operating systems and other frequently used software applications. 

“With a streamlined and modern interface, the software will help users to effortlessly navigate their everyday tasks resulting in faster analytical results, reduced training times and fewer mistakes,” said Simon Wells, Ph.D., Molecular Spectroscopy business unit manager, PerkinElmer Life and Analytical Sciences. “Spectrum Express also responds to the customers’ need for simpler organization and export of data by allowing users to customize their own software interface and by providing a number of printing options and facilities that quickly transfer IR analytical results to Microsoft® software.”  Wells noted that the first version of software will be available in English, German and Japanese with many other languages to follow and that, in addition, the software has built-in local language capabilities.

Spectrum Express is available for shipments in April on Microsoft® Windows® Vista™ (64- and 32-bit versions) and Windows® XP operating systems.

For more information about the Spectrum Express visit, www.perkinelmer.com/spectrumexpress.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements.  Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct.  A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements.  These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging.  Photonics markets include sensors and specialty lighting.